Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

employee- and office-related expenses.

-- In the fourth quarter ended December 31, 2007, Sunesis recorded a $0.3

million additional restructuring charge as a result of the company's

reorganization and reduction in force in the third quarter of 2007.

For the year ended December 31, 2007, an aggregate of $1.6 million in

restructuring charges was recorded. Cash restructuring costs accounted

for approximately $1.1 million of the total $1.6 million restructuring

charge for the year.

-- Sunesis reported a net loss of $8.8 million for the fourth quarter of

2007 and of $38.8 million for the twelve-month period ended December

31, 2007, compared to a reported net loss of $9.0 million and $31.2

million, respectively, for the three-month and twelve-month periods

ended December 31, 2006.

-- In 2008, Sunesis expects net cash used in operating activities of

approximately $30 million - $35 million in the absence of any new

collaborations, compared to $34.5 million in 2007. A decrease in net

cash used in operating activities is anticipated primarily due to the

reorganization effected in August of last year, partially offset by

increased costs associated with clinical trial and other development

activities for SNS-595, SNS-032 and SNS-314.

Conference Call Information

Sunesis' management will host a conference call to review the results of the fourth quarter and the 2007 fiscal year today at 10:30 a.m. EDT. Individual and institutional investors can access the call via 877-604-9668 (U.S. and Canada) or 719-325-4904 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://www.sunesis.com. Please log on to Sunesis' website severa
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... The Alliance for Safe Biologic ... European physicians at the "1 ST EuropaBio ... at the Spanish Ministry of Health, Social Services ... the Spanish Bioindustry Association (ASEBIO), included regulators from ... oncology and rheumatology societies, representatives from a hospital ...
(Date:11/26/2014)... 2014 Whitehouse Laboratories is pleased ... Morris County (New Jersey) Chamber of Commerce as ... business organization in the North Jersey area, offers ... some key clients in the pharmaceutical and biotechnology ... area. Membership enables Whitehouse Laboratories a higher level ...
(Date:11/26/2014)... PA (PRWEB) November 25, 2014 The ... of its official conference and exposition mobile app, ... for free download in the App Store for iOS ... a valuable resource tool before, during and after the ... containing details on exhibiting companies, technical sessions, Conferee Networking ...
(Date:11/26/2014)... N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... 2nd Annual MPN Heroes recognition reception on December 5, ... of Hematology’s annual meeting. The MPN Heroes event will ... contributions in the field of myeloproliferative neoplasms (MPNs). ... show "Nashville," will discuss his family's cancer journey at ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... Omaxe Infrastructure &,Construction Private Ltd(OICPL), a wholly owned subsidiary ... the construction of Allopathic Medical,College and Associated Hospital at ... value of the project is Rs250 crores,approx., The ... with total built up area,of 15.66 lac sq ft. ...
... initial listing requirements with NASDAQ; Stock Symbol ... extends cash runway while focusing on ... 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly Sonus ... announced that the Company has completed its ...
... SHANGHAI, China, Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, ... "the,Company"), a leading Chinese firm specializing ... distribution of probiotics products,today announced it ... Square,Pharmaceutical Co., Ltd. ("Square Pharmaceutical") to ...
Cached Biology Technology:Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... of scientists led by Fred Hutchinson Cancer Research Center ... feasibility of large-scale, standardized protein measurements, which are necessary ... The study, to be published Dec. 8 online in ... scientists, targeted protein-detection approach has the potential to systematically ...
... even a mild traumatic brain injury. While the brain may ... suggest that the brain,s protective coverings may feel the ... mouse trauma model, senior author Dorian McGavern, Ph.D., scientist at ... of the National Institutes of Health, watched specific cells mount ...
... Philadelphia have manipulated key biological events in adult blood ... after the newborn period. Because this fetal hemoglobin is ... (SCD), the cell culture findings may open the door ... "Our study shows the power of a ...
Cached Biology News:Novel method could help bring cancer biomarkers to clinic 2Novel method could help bring cancer biomarkers to clinic 3Concussion secrets unveiled in mice and people 2Concussion secrets unveiled in mice and people 3Flipping a gene switch reactivates fetal hemoglobin, may reverse sickle cell disease 2
Anti-MD-2 (IN) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
p-Bcl-2 (Thr 74)...
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
Biology Products: